Naloxone does not influence cardiovascular responses to mild mental stress in postmenopausal women

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  Litschauer, Brigitte ^a   Schaller, Georg ^a   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cortisol; Hormone replacement therapy; Luteinizing hormone; Reactivity

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; FOLLITROPIN; GESTAGEN; LUTEINIZING HORMONE; NALOXONE; OPIATE ANTAGONIST; PLACEBO; PROGESTERONE;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FOLLITROPIN BLOOD LEVEL; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMIC PARAMETERS; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MENOPAUSAL SYNDROME; MENTAL STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STRESS; VASCULAR RESISTANCE;

BLOOD PRESSURE; COLOR PERCEPTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUTEINIZING HORMONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OVARY; POSTMENOPAUSE; STRESS, PSYCHOLOGICAL;

EID: 27144478011     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01113.2004     Document Type: Article

References (43)

1. Abel TW and Rance NE. Proopiomelanocortin gene expression is decreased in the infundibular nucleus of postmenopausal women. Mol Brain Res 69: 202-208, 1999.
2. Al'Absi M, Wittmers LE, Ellestad D, Nordehn G, Kim SW, Kirschbaum C, and Grant JG. Sex differences in pain and hypothalamic-pituitary adrenocortical responses to opioid blockade. Psychosom Med 66: 198-206, 2004.
3. Bairey Merz CN, Kop W, Krantz DS, Helmers KF, Berman DS, and Rozanski A. Cardiovascular stress responses and coronary artery disease: evidence of an adverse postmenopausal effect in women. Am Heart J 135: 881-887, 1998.
4. Baranowska B. Are disturbances in opioid and adrenergic systems involved in the hormonal dysfunction of anorexia nervosa? Psychoneuroendocrinology 15: 371-378, 1990.
5. Barret-Connore E and Bush TL. Estrogen and coronary heart disease in women. JAMA 265: 1861-1867, 1991.
6. Belfort MA, Saade GR, Snabes M, Dunn R, Moise KJ, Cruz A, and Young R. Hormonal status affects the reactivity of the cerebral vasculature. Am J Obstet Gynecol 172: 1273-1278, 1995.
7. Bouloux PM, Grossman A, Al-Damluji S, Bailey T, and Besser M. Enhancement of the sympathoadrenal response to the cold-pressor test by naloxone in man. Clin Sci (Colch) 69: 365-368, 1985.
8. Brownley KA, Hinderliter AL, West SG, Grewen KM, Steege JF, Girdler SS, and Light KC. Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause. Am J Obstet Gynecol 190: 1052-1058, 2004.
9. Burleson MH, Malarkey WB, Cacioppo JT, Poehlmann KM, Klecolt-Glaser JK, Berntson GG, and Glaser R. Postmenopausal hormone replacement: effects on autonomic, neuroendocrine, and immune reactivity to brief psychological Stressors. Psychosom Med 60: 17-25, 1998.
10. Burnett FE, Scott LV, Weaver MG, Medbak SH, and Dinan TG. The effect of naloxone on adrenocorticotropin and cortisol release: evidence for a reduced response in depression. J Affect Disord 53: 263-268, 1999.
11. Cicero TJ, Nock B, O'Connor L, and Meyer ER. Role of steroids in sex differences in morphine-induced analgesia: activational and organizational effects. JPET 300: 695-701, 2002.
12. Coiro V, D'Amato L, Marchesi C, Capretti L, Volpi R, Roberti G, Cerri L, and Chiodera P. Luteinizing hormone and cortisol responses to naloxone in normal weight women with bulimia. Psychoneuroendocrinology 15: 463-470, 1990.
13. D'Amico JF, Greendale GA, Lu JK, and Judd HL. Induction of hypothalamic opioid activity with transdermal estradiol administration in postmenopausal women. Fertil Steril 55: 754-758, 1991.
14. Dawood MY, Khan-Dawood FS, and Ramos J. The effect of estrogen-progestin treatment on opioid control of gonadotropin and prolactin secretion in postmenopausal women. Am J Obstet Gynecol 155: 1246-1251, 1986.
15. Facchineti F, Fioroni L, Martignoni E, Sances G, Costa A, and Genazzani AR. Changes of opioid modulation of the hypothalamopituitary-adrenal axis in patients with severe premenstraul syndrome. Psychosom Med 56: 418-422, 1994.
16. Fontana F, Bernardi P, Pich EM, Boschi S, de Iasio R, Spampinatos S, and Grossi G. Opioid peptide modulation of circulatory and endocrine response to mental stress in humans. Peptides 18: 169-175, 1997.
17. Gilligan DM, Quyyumi AA, Cannon RO, Johnson GB, and Schenke WH. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89: 2545-2551, 1994.
18. Grossman A. Opioids and stress in man. J Endocrinol 119: 377-381, 1988.
19. Rest B, Sarton E, and Dahan A. Gender differences in opioid-mediated analgesia: animal and human studies. Anesthesiology 93: 539-547, 2000.
20. Komesaroff PA, Esler MD, and Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 84: 606-610, 1999.
21. Krantz WB and Manuck SB. Acute psychophysiological reactivity and risk of cardiovascular disease: a review and methodological critique. Psychol Bull 96: 435-464, 1984.
22. Lim SC, Caballero E, Arora S, Smakowsky P, Bashoff EM, Brown FM, Logerfo FW, Horton ES, and Veves A. The effect of hormon replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab 84: 4159-4164, 1999.
23. Lindheim SR, Legro RS, Morris RS, Wong IL, Tran DQ, Vijod MA, Stanczyk FZ, and Lobo RA. The effect of progestins on behavioral stress responses in postmenopausal women. J Soc Gynecol Investig 1: 79-83, 1994.
24. Matthews KA, Flory JD, Owens JF, Harris KF, and Berga SL. Influence of estrogene replacement therapy on cardiovascular responses to stress of healthy postmenopausal women. Psychophysiology 38: 391-398, 2001.
25. McCubbin JA, Surwit RS, Williams RB, Nemeroff CB, and McNeilly M. Altered pituitary hormone response to naloxone in hypertension development. Hypertension 14: 636-644, 1989.
26. Mercuro G, Balloi C, De Candia G, Panzuto MG, Zoncu S, Cagnacci A, Benedetto G, and Cherchi A. Effects of transdermal estrogen administration on peripheral vascular responsiveness in menopausal women. Int J Angiology 6: 237-240, 1997.
27. Meyer WR, Costello N, Straneva P, West W, Copeland K, and Girdler S. Effect of low-dose estrogen on hemodynamic response to stress. Fertil Steril 75: 394-399, 2001.
28. Morris M, Salmon P, Steinberg II, Sykes EA, Bouloux P, Newbould E, McLoughlin L, Besser GM, and Grossman A. Endogenous opioids modulate the cardiovascular response to mental stress. Psychoneuroendocrinology 15: 185-192, 1990.
29. Nappi C, Petraglia F, Gambardella A, De-Masellis G, Di-Carlo C, Genazzani AR, and Montemagno U. Relationship between cerebrospinal fluid β-endorphin and plasma pituitary-gonadal hormone levels in women. J Endocrinol Invest 13: 149-153, 1990.
30. Negus SS and Mello NK. Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement. JPET 290: 1132-1140, 1999.
31. Owens JF, Stoney CM, and Matthews KA. Menopausal status influences ambulatory blood pressure levels and blood pressure changes during mental stress. Circulation 88: 2794-2802, 1993.
32. Reid RL, Quigley ME, and Yen SSC. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women. J Clin Endocrinol Metab 57: 1107-1110, 1983.
33. Saab PG, Matthews KA, Stoney CM, and McDonald RH. Pre-menopausal and postmenopausal women differ in their responses to behavioral stressors. Psychophysiology 26: 270-280, 1989.
34. Sarrel PM. Ovarian hormones and the circulation. Maturitas 590: 287-298, 1990.
35. Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE, and Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: 10 year follow-up from the nurses health study. N Engl J Med 325: 756-762, 1991.
36. Sudhir K, Esler MD, Jennings GL, and Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension 30: 1538-1543, 1997.
37. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712, 2004.
38. Volterrant M, Rosano G, Coats A, Beale C, and Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 99: 119-122, 1995.
39. Weitz G, Elam M, Born J, Fehm HL, and Dodt C. Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. J Clin Endocrinol Metab 86: 344-348, 2001.
40. West SG, Hinderliter AL, Wells EC, Girdler SS, and Light KC. Light. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 184: 926-933, 2001.
41. Willemsen GHM, De Geus EJC, Klaver CHAM, Van Doornen LJP, and Carroll D. Ambulatory monitoring of the impedance cardiogram. Psychophysiology 33: 184-193, 1996.
42. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
43. Zubieta JK, Dannals R, and Frost J. Gender and age influences on human brain μ opioid receptor binding measured by PET. Am J Psychiatry 156: 842-848, 1999.